Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer
Open accessAbstract
A common key regulator of oncogenic signaling pathways in multiple tumor types is the unique isomerase Pin1. However, available Pin1 inhibitors lack the required specificity and potency for inhibiting Pin1 function in vivo. By using mechanism-based screening, here we find that all-trans retinoic acid (ATRA)--a therapy for acute promyelocytic leukemia (APL) that is considered the first example of targeted therapy in cancer, but whose drug target remains elusive--inhibits and degrades active Pin1 selectively in cancer cells by directly binding to the substrate phosphate- and proline-binding pockets in the Pin1 active site. ATRA-induced Pin1 ablation degrades the protein encoded by the fusion oncogene PML-RARA and treats APL in APL cell and animal models as well as in human patients. ATRA-induced Pin1 ablation also potently inhibits triple-negative breast cancer cell growth in human cells and in animal models by acting on many Pin1 substrate oncogenes and tumor suppressors. Thus, ATRA simultaneously blocks multiple Pin1-regulated cancer-driving pathways, an attractive property for treating aggressive and drug-resistant tumors.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The continued scrutiny of natural retinoids is likely because RA is a natural drug, blocks multiple disease signaling pathways, is less selective than some synthetic retinoids, and has long been used in combinatorial therapy and is well known by clinicians.
“The reasons are likely combinatorial: RA is a natural drug, blocks multiple disease signaling pathways12, in opposition to some synthetic retinoids that are very selective to a single receptor-mediated signaling pathway, and it has been used for many years in combinatorial therapy and thus well known by clinicians.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [12]
RA promoted terminal differentiation of leukemic cells while reducing their proliferation.
“RA promoted terminal differentiation of leukemic cells while reducing their proliferation.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [12]
The antitumoral activity of RA (enhanced by cooperation with arsenic trioxide) was due to inhibition and degradation of prolyl isomerase Pin1, which has a critical role in coordinating multiple phosphorylation events during oncogenesis.
“The antitumoral activity of RA (enhanced by cooperation with arsenic trioxide)11 was due to inhibition and degradation of prolyl isomerase Pin1, which has a critical role in coordinating multiple phosphorylation events during oncogenesis12.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [12]
In the case of cancer, recent studies indicate that the antitumoral activity of RA might be greatly enhanced with formulations that extend the in vivo half-life of RA.
“In the case of cancer, recent studies indicate that the antitumoral activity of RA might be greatly enhanced with formulations that extend the in vivo half-life of RA12.”
From Advances and challenges in retinoid delivery systems in regenerative and therapeutic medicine (2020) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · see citing works
<i>Coot</i> : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · see citing works
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. D. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 27,510 · see citing works
The CCP4 suite: programs for protein crystallography
Number Collaborative Computational Project (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,299 · see citing works
<i>MolProbity</i> : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115 · see citing works
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, S. R., Chai, J., Lu, J., Zhoa, L., Gu, L.-J., & Wang, Z.-Y. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445 · see citing works
Shultz, L. D., Lyons, B. L., Burzenski, L. M., Gott, B., Chen, X., Chaleff, S., Kotb, M., Gillies, S. D., King, M., Mangada, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.10.6477 · Cited by 1,736 · see citing works
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611 · see citing works
Self-citationMain-chain Bond Lengths and Bond Angles in Protein Structures
Laskowski, R. A., Moss, D. S., & Thornton, J. M. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1351 · Cited by 1,217 · see citing works
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., Lyssiotis, C. A., Aldape, K., Cantley, L. C., & Lu, Z. (2012) · Nature Cell Biology · doi:10.1038/ncb2629 · Cited by 910 · see citing works
Self-citationLanotte, M., Martin-Thouvenin, V., Najman, S. J., Balerini, P., Valensi, F., & Berger, R. (1991) · Blood · doi:10.1182/blood.v77.5.1080.1080 · Cited by 881 · see citing works
Yaffe, M. B., Schutkowski, M., Shen, M., Zhou, X. Z., Stukenberg, P. T., Rahfeld, J., Xu, J., Kuang, J., Kirschner, M. W., Fischer, G. S., et al. (1997) · Science · doi:10.1126/science.278.5345.1957 · Cited by 770 · see citing works
Self-citationThe prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease
Lu, K. P., & Zhou, X. Z. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2261 · Cited by 682 · see citing works
Self-citationProlyl cis-trans isomerization as a molecular timer
Lu, K. P., Finn, G., Lee, T. H., & Nicholson, L. K. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.35 · Cited by 655 · see citing works
Self-citationRyo, A., Suizu, F., Yoshida, Y., Perrem, K., Liou, Y., Wulf, G. M., Rottapel, R. K., Yamaoka, S., & Lu, K. P. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00490-8 · Cited by 632 · see citing works
Self-citationThe deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network
Song, M. S., Salmena, L., Carracedo, A., Egia, A., Lo-Coco, F., Teruya-Feldstein, J., & Pandolfi, P. P. (2008) · Nature · doi:10.1038/nature07290 · Cited by 548 · see citing works
Self-citationWulf, G. M., Ryo, A., Wulf, G. G., Lee, S. W., Niu, T., Petkova, V., & Lu, K. P. (2001) · The EMBO Journal · doi:10.1093/emboj/20.13.3459 · Cited by 529 · see citing works
Self-citationAcute promyelocytic leukaemia: novel insights into the mechanisms of cure
de Thé, H., & Zhu, C. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2943 · Cited by 490 · see citing works
Ryo, A., Nakamura, M., Wulf, G. M., Liou, Y.-C., & Lu, K. P. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-793 · Cited by 467 · see citing works
Self-citationThe Death-Associated Protein Kinases: Structure, Function, and Beyond
Bialik, S., & Kimchi, A. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142615 · Cited by 441 · see citing works
Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration
Liou, Y., Sun, A., Ryo, A., Zhou, X. Z., Yu, Z.-X., Huang, H.-K., Uchida, T., Bronson, R. T., Bing, G., Li, X., et al. (2003) · Nature · doi:10.1038/nature01832 · Cited by 436 · see citing works
Self-citationMuindi, J. R., Frankel, S., Miller, W. J., Jakubowski, A. A., Scheinberg, D., Cw, Y., Dmitrovsky, E., & Warrell, R. J. (1992) · Blood · doi:10.1182/blood.v79.2.299.bloodjournal792299 · Cited by 408 · see citing works
N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat.
Moon, R. C., Thompson, H. J., Becci, P. J., et al. (1979) · PubMed · Cited by 386 · see citing works
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
Nasr, R., Guillemin, M.-C., Ferhi, O., Soilihi, H., Pérès, L., Berthier, C., Rousselot, P. H., Robledo-Sarmiento, M., Lallemand-Breitenbach, V., Gourmel, B., et al. (2008) · Nature Medicine · doi:10.1038/nm.1891 · Cited by 354 · see citing works
Self-citationBoehm, M. F., Zhang, L., Zhi, L., McClurg, M. R., Berger, E. M., WAGONER, M., Mais, D. E., Suto, C. M., Davies, P. J. A., Heyman, R. A., et al. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00016a018 · Cited by 342 · see citing works
Acute leukemia with promyelocytic features in PML/RARα transgenic mice
He, L.-Z., Tribioli, C., Rivi, R., Peruzzi, D., Pelicci, P. G., Soares, V. C., Cattoretti, G., & Pandolfi, P. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5302 · Cited by 339 · see citing works
Self-citationLoss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes
Liou, Y.-C., Ryo, A., Huang, H.-K., Lu, P., Bronson, R. T., Fujimori, F., Uchida, T., Hunter, T. R., & Lu, K. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.032404099 · Cited by 338 · see citing works
Self-citationSelective Inactivation of Parvulin-Like Peptidyl-Prolyl cis/trans Isomerases by Juglone
Hennig, L., Christner, C., Kipping, M., Schelbert, B., Rücknagel, K. P., Grabley, S., Küllertz, G., & Fischer, G. S. (1998) · Biochemistry · doi:10.1021/bi973162p · Cited by 321 · see citing works
Muindi, J., Frankel, Sr., Miller, W. J., Jakubowski, A., Scheinberg, D., Young, C., Dmitrovsky, E., & Warrell, R. J. (1992) · Blood · doi:10.1182/blood.v79.2.299.299 · Cited by 314 · see citing works
Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia.
Muindi, J. R., Frankel, S. R., Huselton, C. A., DeGrazia, F., Garland, W., Young, C. W., & Warrell, R. P. (1992) · PubMed · Cited by 286 · see citing works
Nakamura, K., Greenwood, A., Binder, L. I., Bigio, E. H., Denial, S., Nicholson, L. K., Zhou, X. Z., & Lu, K. P. (2012) · Cell · doi:10.1016/j.cell.2012.02.016 · Cited by 255 · see citing works
Self-citationLu, P.-J., Zhou, X. Z., Liou, Y.-C., Noel, J. P., & Lu, K. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c100228200 · Cited by 244 · see citing works
Self-citationModern Approaches to Treating Acute Promyelocytic Leukemia
Sanz, M. Á., & Lo‐Coco, F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.1067 · Cited by 221 · see citing works
Self-citationMice Lacking Pin1 Develop Normally, but Are Defective in Entering Cell Cycle from G0 Arrest
Fujimori, F., Takahashi, K., Uchida, C., & Uchida, T. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1736 · Cited by 216 · see citing works
Connolly, R. M., Nguyen, N. K., & Sukumar, S. V. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3175 · Cited by 211 · see citing works
Prolyl isomerase Pin1 in cancer
Lu, Z., & Hunter, T. R. (2014) · Cell Research · doi:10.1038/cr.2014.109 · Cited by 203 · see citing works
Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism
Langenfeld, J. E., Kiyokawa, H., Sekula, D., Boyle, J., & Dmitrovsky, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.22.12070 · Cited by 202 · see citing works
Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis
Wulf, G. M., Garg, P., Liou, Y., Iglehart, D. J., & Lu, K. P. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600323 · Cited by 199 · see citing works
Self-citationLee, T. H., Chen, C.-H., Suizu, F., Huang, P., Schiene-Fischer, C., Daum, S., Zhang, Y. J., Goate, A., Chen, R.-H., Zhou, X. Z., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.005 · Cited by 183 · see citing works
Self-citationPin1 and Par14 Peptidyl Prolyl Isomerase Inhibitors Block Cell Proliferation
Uchida, T., Takamiya, M., Takahashi, M., Miyashita, H., Ikeda, H., Terada, T., Matsuo, Y., Shirouzu, M., Yokoyama, S., Fujimori, F., et al. (2003) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00310-1 · Cited by 175 · see citing works
Prolyl‐isomerase Pin1 controls normal and cancer stem cells of the breast
Rustighi, A., Zannini, A., Tiberi, L., Sommaggio, R., Piazza, S., Sorrentino, G., Nuzzo, S., Tuscano, A., Eterno, V., Benvenuti, F., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302909 · Cited by 160 · see citing works
Rego, E. M., Kim, H. T., Ruiz-Argüelles, G. J., Undurraga, M. S., Uriarte, M. D. R., Jácomo, R. H., Gutiérrez‐Aguirre, C. H., Melo, R. A. M., Bittencourt, R., Pasqüini, R., et al. (2013) · Blood · doi:10.1182/blood-2012-08-449918 · Cited by 146 · see citing works
Self-citationMin, S. H., Lau, A. W., Lee, T. H., Inuzuka, H., Wei, S., Huang, P., Shaik, S., Lee, D. Y., Finn, G., Balaštík, M., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.04.012 · Cited by 146 · see citing works
Self-citationStructural Basis for High-Affinity Peptide Inhibition of Human Pin1
Zhang, Y., Daum, S., Wildemann, D., et al. (2007) · ACS Chemical Biology · doi:10.1021/cb7000044 · Cited by 138 · see citing works
Self-citationArrieta, O. G., la Rosa, C. H. G.-D., Aréchaga-Ocampo, E., Villanueva-Rodríguez, G., Cerón-Lizárraga, T., Martínez-Barrera, L. M., Vázquez-Manríquez, M. E., Ríos-Trejo, M. Á., Álvarez-Avitia, M. Á., Hernández‐Pedro, N., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6452 · Cited by 125 · see citing works
Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics
Lu, K. P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00218-6 · Cited by 123 · see citing works
Self-citationEpigallocatechin-gallate Suppresses Tumorigenesis by Directly Targeting Pin1
Urusova, D. V., Shim, J., Kim, D. J., Jung, S. K., Zykova, T. A., Carper, A., Bode, A. M., & Dong, Z. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0301 · Cited by 122 · see citing works
Suizu, F., Ryo, A., Wulf, G. M., Lim, J., & Lu, K. P. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1463-1479.2006 · Cited by 117 · see citing works
Self-citationDeCensi, A., Robertson, C., Guerrieri‐Gonzaga, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.3797 · Cited by 114 · see citing works
Sheng, N., Xie, Z., Wang, C., Bai, G., Zhang, K., Zhu, Q., Song, J., Guillemot, F., Chen, Y., Lin, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009244107 · Cited by 106 · see citing works
Pin1 inhibitors: Pitfalls, progress and cellular pharmacology
Moore, J. D., & Potter, A. J. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.088 · Cited by 105 · see citing works
Nakano, A., Koinuma, D., Miyazawa, K., Uchida, T., Saitoh, M., Kawabata, M., Hanai, J.-I., Akiyama, H., Abe, M., Miyazono, K., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804659200 · Cited by 103 · see citing works
Liao, Y., Wei, Y., Zhou, X., Yang, J. Y., Dai, C., Chen, Y. J., Agarwal, N., Sarbassov, D. D., Shi, D., Yu, D., et al. (2009) · Oncogene · doi:10.1038/onc.2009.98 · Cited by 94 · see citing works
Self-citationKogan, S. C., Hong, S.-H., Shultz, D. B., et al. (2000) · Blood · doi:10.1182/blood.v95.5.1541.005k28_1541_1550 · Cited by 91 · see citing works
Wildemann, D., Erdmann, F., Alvarez, B. H., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060036n · Cited by 90 · see citing works
The Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis via Erk Signaling Activation
Luo, M., Gong, C., Chen, C.-H., Hu, H., Huang, P., Zheng, M., Yao, Y., Wei, S., Wulf, G. M., Lieberman, J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.002 · Cited by 89 · see citing works
Self-citationRamlau, R., Zatloukal, P., Jassem, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2614 · Cited by 89 · see citing works
Ablain, J., Leiva, M., Pérès, L., Fonsart, J., Anthony, E., & de Thé, H. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20122337 · Cited by 87 · see citing works
Luo, M.-L., Gong, C., Chen, C.-H., Lee, D. Y., Hu, H., Huang, P., Yao, Y., Guo, W., Reinhardt, F., Wulf, G. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2785 · Cited by 85 · see citing works
Self-citationPhase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
Budd, G. T., Adamson, P. C., Gupta, M. K., Homayoun, P., Sandstrom, S. K., Murphy, R. F., McLain, D., Tuason, L. J., Peereboom, D. M., Bukowski, R. M., et al. (1998) · PubMed · Cited by 84 · see citing works
Rajbhandari, P., Finn, G., Solodin, N. M., Singarapu, K. K., Sahu, S. C., Markley, J. L., Kadunc, K., Miner, S. J., Kariagina, A., Haslam, S. Z., et al. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.06073-11 · Cited by 77 · see citing works
Self-citationdos Santos, G. A., Lima, R. S., Pestana, C. R., Lima, A. S., Scheucher, P. S., Thomé, C. H., Teixeira, H. L. G., Santana-Lemos, B. A. A., Lucena-Araujo, A. R., Rodrigues, F. P., et al. (2011) · Leukemia · doi:10.1038/leu.2011.216 · Cited by 73 · see citing works
Self-citationLam, P. B., Burga, L. N., Wu, B. P., Hofstatter, E. W., Lu, K. P., & Wulf, G. M. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-91 · Cited by 73 · see citing works
Self-citationCdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT
Stanya, K. J., Liu, Y., Means, A. R., & Kao, H. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200806172 · Cited by 59 · see citing works
Gianni’, M., Boldetti, A., Guarnaccia, V., Rambaldi, A., Parrella, E., Raška, I., Rochette‐Egly, C., Sal, G. D., Rustighi, A., Terao, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2603 · Cited by 58 · see citing works
The peptidyl–prolyl isomerase Pin1 regulates phospho-Ser77 retinoic acid receptor α stability
Brondani, V., Schefer, Q., Hamy, F., & Klimkait, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.130 · Cited by 41 · see citing works
Effects of All-Trans Retinoic Acid on Th1- and Th2-Related Chemokines Production in Monocytes
Tsai, Y.-C., Chang, H., Chang, T., et al. (2008) · Inflammation · doi:10.1007/s10753-008-9095-x · Cited by 37 · see citing works
Gausdal, G., Wergeland, A., Skavland, J., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.39 · Cited by 36 · see citing works
The rs2233678 Polymorphism in PIN1 Promoter Region Reduced Cancer Risk: A Meta-Analysis
Li, Q., Li, Q., Zhao, D. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068148 · Cited by 31 · see citing works
Chen, H., & Juchau, M. R. (1998) · Biochemical Journal · doi:10.1042/bj3360223 · Cited by 31 · see citing works
Photoaffinity labeling of retinoic acid-binding proteins.
Bernstein, P. S., Choi, S. Y., Ho, Y. C., et al. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.3.654 · Cited by 27 · see citing works
Receptor Binding Assays for HTS and Drug Discovery
Auld, D. S., Farmen, M. W., Kahl, S. D., Kriauciunas, A., McKnight, K. L., Montrose, C., & Weidner, J. R. (2012) · Europe PMC (PubMed Central) · Cited by 16 · see citing works
Jain, P., Kantarjian, H., Estey, E., Pierce, S., Cortes, J., Lopez-Berestein, G., & Ravandi, F. (2014) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.08.004 · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517 · see citing works
Kozono, S., Lin, Y.-M., Seo, H.-S., Pinch, B., Lian, X., Qiu, C., Herbert, M. K., Chen, C.-H., Tan, L., Gao, Z. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05402-2 · Cited by 168 · see citing works
Self-citationAdvances and challenges in retinoid delivery systems in regenerative and therapeutic medicine
Ferreira, R., Napoli, J., Enver, T., Bernardino, L., & Ferreira, L. (2020) · Nature Communications · doi:10.1038/s41467-020-18042-2 · Cited by 138 · see citing works
- Authors
- Wei, S., Kozono, S., Kats, L., Nechama, M., Li, W., Guarnerio, J., Luo, M., You, M.-H., Yao, Y., Kondo, A., Hu, H., Bozkurt, G., Moerke, N. J., Cao, S., Reschke, M., Chen, C.-H., Rego, E. M., Lo-Coco, F., Cantley, L. C., Lee, T. H., Wu, H., Zhang, Y., Pandolfi, P. P., Zhou, X. Z., & Lu, K. P.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- The University of Texas at Austin (US)
- Harvard University (US)
- Universidade de São Paulo (BR)
- Corresponding author
- Zhou, Xiao Zhen
- Lu, Kun Ping
- ORCID
- Venue
- Nature Medicine
- Published
- 2015-04-13
- Volume
- 21
- Issue
- 5
- Pages
- 457-466
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC4425616
- OpenAlex
- W2016132261
- Cited by
- 272
- References
- 74
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 25 · 2023: 25 · 2022: 24 · 2021: 26 · 2020: 28 · 2019: 30 · 2018: 32 · 2017: 19 · 2016: 21 · 2015: 11 · 2014: 1
- FWCI
- 12.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Université de Strasbourg
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL111430)
- National Institute on Drug Abuse (R03DA031663)
- National Cancer Institute (R01CA167677)
- National Institute of General Medical Sciences (R01GM104896)
- National Institute of Allergy and Infectious Diseases (R37AI050872)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
- Keywords
- Pin1, all-trans retinoic acid, acute promyelocytic leukemia, triple-negative breast cancer, protein degradation, drug target identification, oncogenic signaling, drug resistance
- MeSH terms
- NIMA-Interacting Peptidylprolyl Isomerase, Animals, Antineoplastic Agents, Breast Neoplasms, Catalysis, Dose-Response Relationship, Drug, Female, Fibroblasts, Humans, Mice, Inbred BALB C, Neoplasm Transplantation, Phosphates, Phosphorylation, Proline, Tretinoin, Leukemia, Promyelocytic, Acute, Gene Expression Regulation, Neoplastic, Gene Expression Regulation, Leukemic, Mice, Knockout, Peptidylprolyl Isomerase, Catalytic Domain, Cell Line, Tumor, Mice, HEK293 Cells, MCF-7 Cells, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
